A US jury recently ordered Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc $235 million ($234.1 million in lost profits and $1.4 million in royalties) for infringing a patent covering its blood pressure drug Coreg.
A US federal jury found that Teva Pharmaceutical Industries Ltd infringed the patent with its sales of a generic version of the drug with a label indicating it could be used for treating chronic heart failure. The generic version of Coreg (called Carvedilol) created by Teva Pharmaceutical Industries was approved for use in 2007 by the US Food and Drug Administration. Carvedilol is a beta-blocker used to treat heart failure and high blood pressure.
The jury rejected Teva pharmaceutical Industries’s argument that the patent was invalid. Teva Pharmaceutical Industries has said that the company is now considering an appeal.